With regard to the lower immunogenicity of the VEGF2-derived epitope than that derived from VEGFR1, further studies are warranted to determine whether the VEGFR2-specific immune response can be induced more effectively in newly-diagnosed patients with glioma, with higher immunoresponsiveness, than immunosuppressed patients with recurrent high-grade glioma. The gene discussed is FLT1; the disease is glioma.